InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its new president and CEO.

Greenberg brings 25 years of experience in the life sciences industry to InCarda. His background includes roles as a CEO, venture investor and lead board member for companies developing new biopharmaceuticals, medical devices and healthcare technologies.

Before joining InCarda, he served as an emergency physician and emergency department administrator at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massachusetts, US.

He replaces interim CEO Carlos Schuler, a co-founder of the company, who will now take on the role of chief technology officer.

InCarda Therapeutics executive chairman Dan Welch stated: “Myles has an innate understanding of the challenges in properly treating cardiac arrythmias like paroxysmal atrial fibrillation [PAF], where underdiagnosis and undermanagement lead to disease progression, poor outcomes and significant strain on the healthcare system.

“We are confident that he is the right leader to build InCarda into a key driver of positive change that can address these challenges and improve the standard of care for physicians and patients.”

Greenberg is set to lead the company as it progresses with the clinical development of its orally inhaled treatment, flecainide.

An antiarrhythmic medication, flecainide has been approved in the US for more than three decades for oral use in chronic treatment.

It is prescribed to decrease the risk of recurrent and symptomatic PAF in individuals who do not have structural heart disease.

Greenberg stated: “InCarda’s mission is to enable the growing number of PAF sufferers to take more control of their health by developing a product designed to allow patients eventually to treat their abnormal heart rhythm and symptoms at home. 

“If we are successful, we can improve patients’ quality of life and help them avoid unnecessary hospitalisations and other complications of their AF.”